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Abstract
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Chylothorax, which is defined as the presence of chyle in the pleural space, is often caused by
malignancy. However, chylothorax as a result of underlying CLL is exceedingly rare in the
literature. Chyle contains fat soluble vitamins and lymphocytes, meaning that its collection into
the pleural space may further exacerbate the immunosupressed state of an individual with CLL.
Here, we report three cases of patients with CLL who developed chylothorax, and their
management. Chylothorax, although rare with CLL, should be considered in the differential
diagnosis when patients with CLL present with pleural effusions, especially if recurrent.
Discovery of a chylothorax may indicate the need for further treatment of CLL.

Introduction

Author Manuscript

Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in the Western
hemisphere. During the course of the disease, CLL patients may develop thoracic
complications including pleural effusions. However, most of the reported literature describes
pulmonary complications related to pneumonia. [1] There is scant literature describing
pleural effusions related to CLL. Here, we report the outcomes of 3 cases in which patients
with CLL were found to have chylous effusions at varying stages of disease.
Chylous pleural effusions are defined by the presence of chyle (a lymphocyte rich fluid)
accumulating in the pleural space, often secondary to disruption or obstruction of the
thoracic duct[2,3]. Chyle will accumulate in the right pleural space if the disruption occurs
below the fifth thoracic vertebra, however if the thoracic duct is disrupted above the fifth
thoracic vertebra, the chylothorax will typically occur in the left pleural space [4,5]. The
majority of chylous effusions are unilateral and on the right side.
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Chylothorax is caused either by malignancy, which represents about half of all cases,
trauma, which accounts for about a third of cases, or other miscellaneous conditions
including sarcoid, tuberculosis, lupus, lymphangioleiomyomatosis and cirrhosis, which
collectively make up about 14% of cases[6]. While malignancy accounts for about half of all
chylothoraces, there have only been twelve reports of chylothorax related to CLL.[6]
Case 1

Author Manuscript

A 78 year old male with a remote history of hairy cell leukemia treated with interferon and
cladribine, prostate cancer (Gleason 4+5, treated with prostatectomy and hormonal
manipulation and then abiraterone upon progression), diastolic congestive heart failure
(CHF) and CLL with 13q deletion (see Table 1 for detailed prognostic markers) and
associated hypogammaglobulinemia, presented with recurrent shortness of breath. Prior to
developing shortness of breath, his CLL had been observed clinically for five years before
his white blood cell count (WBC) rose to 220 × 109/L and he developed dyspnea on
exertion. At the time, as none of the novel targeted agents were commercially available, he
was started on pentostatin, cyclophosphamide and rituximab (PCR) for two cycles.
Additionally he was given furosemide for dyspnea and bilateral pleural effusions presumed
secondary to CHF. Following completion of his second cycle of PCR his shortness of breath
worsened and a CT scan showed increased bilateral pleural effusions, which persisted
despite treatment with diuretics. Therapeutic thoracentesis yielded a turbid, yellow exudative
effusion with an elevated triglyceride count of 347 consistent with a chylothorax. Pleural
fluid flow cytometry yielded fluid with a monoclonal B cell population expressing
CD19,dim CD20, CD5, and CD23 markers, consistent with CLL (Table 2).
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Initially the patient was recommended to undergo placement of a long term indwelling
catheter [7] or video-assisted thorascopic surgery with pleurodesis for management of his
effusions. However, once the diagnosis of chylothorax was made in the setting of CLL the
decision was to change CLL-directed treatment to Bendamustine and Rituxan for two cycles
with improvement in the quantity of the effusions. He did not require treatment again for
over two years upon development of worsening adenopathy. At recurrence, recently
approved ibrutinib was started. Single agent therapy was tolerated for five months until he
developed new onset atrial fibrillation. In light of worsening effusions off of therapy, the
patient had a pleurX catheter placed followed by the initiation of Obinutuzumab combined
with ibrutinib. Combination therapy was complicated by recurrent atrial fibrillation and
eventual development of recurrent serosanguineous pleural effusions requiring therapy
discontinuation. Approximately one month after discontinuation, his pleural effusions
recurred causing recurrent symptoms. At this time, given recurrent atrial fibrillation, he was
treated with idelalisib. The patient developed a significant grade III psoriatic type rash
requiring discontinuation of the drug only three weeks after its initiation. Six weeks later he
again developed worsening effusions causing dyspnea and he was rechallenged with
ibrutinib. While on ibrutinib therapy he developed recurrent staphylococcal empyemas
coupled with worsening pleural effusions. In light of significant debilitation and infectious
complications he was referred to home hospice where he later expired.
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An 81 year old female with no previous diagnosis of malignancy initially presented with
cough, dyspnea on exertion and a 40 pound weight loss over several months. Physical exam
revealed bilateral cervical and axillary adenopathy as well as decreased breath sounds and
dullness to percussion over the bilateral lower lung fields. A complete blood count was
normal without any cytopenias and a normal lymphocyte count. A CT scan of her chest
revealed a large right and moderate left pleural effusion as well as extensive axillary,
mediastinal, hilar adenopathy. Thoracentesis yielded two liters of a classic milky appearing
exudative effusion, however a triglyceride level was not sent on this specimen. Cytology and
flow cytometry showed a small population of monoclonal B cells in a background of
polymorphous lymphocytes with a few atypical lymphocytes (Table 2). This led to an
axillary lymph node biopsy consistent with chronic lymphocytic leukemia.
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Chemotherapy was recommended and the patient completed three cycles of the
bendamustine and rituximab. Post-chemotherapy CT scans showed a partial response with
decrease in adenopathy, however, moderate pleural effusions remained. Due to persistent
symptoms of dyspnea on exertion, another thoracentesis was performed which was again
chylous in appearance. Despite the improvement in adenopathy the continued chylous
effusion suggested persistent disease and further treatment was recommended. The patient
deferred treatment and she presented to the emergency room with hyponatremia and large
bilateral pleural effusions causing respiratory failure. Despite aggressive measures and
repeat large volume thoracentesis confirming chylothorax, the patient passed away of
pulmonary complications.
Case 3
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A 77 year old female, originally diagnosed with CLL in 2009, was being followed clinically
until she developed worsening anemia and thrombocytopenia in 2015. At that time, she also
complained of shortness of breath and began treatment with obinutuzumab monotherapy.
After one cycle of treatment, she was admitted to the hospital for worsening shortness of
breath. She was noted to have bilateral pleural effusions. The effusions were drained and
were consistent with a chylous effusion with a triglyceride level of 311 (Table 2). Her
effusions recurred and an indwelling pleural catheter was placed on the right side, which
drained 700 cc to one liter of fluid daily. She was started on idelalisib to better control her
disease but she continued to have significant pleural fluid drainage. After two months of
treatment with idelalisib, she was found to have an empyema growing S. sanguinis which
required six weeks of ceftriaxone. Given ongoing serious infection, idelalisib was
discontinued and radiation treatment was pursued. She received 2400 cGy of radiation in 12
fractions to her thoracic duct and mediastinum. After radiation, her effusions improved and
the patient has remained off systemic treatment for the past 17 months.

Discussion
CLL can present with diffuse lymphadenopathy, however mediastinal lymphadenopathy
severe enough to obstruct the thoracic duct is rare [8–10]. CLL diagnosis is not traditionally
associated with chylothorax [11], although other types of pleural effusions may occur more
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commonly with long standing CLL [12]. Some of the proposed mechanisms for CLL
induced chylothorax include the possibility that large amounts of abnormal lymphocytes in
CLL may cause sludging in the lymphatic system, resulting in a pseudo-obstruction of the
thoracic duct or lymphatics draining the pleura, or that the sludging may lead to distention of
the thoracic duct making it more susceptible to rupture causing chyle to leak into the pleural
space [5].

Author Manuscript

Chylothorax typically presents as an exudative effusion with a milky white appearance,
however this is not a reliable diagnostic marker. A recent retrospective analysis of 74
patients previously diagnosed with chylothorax found only 44% to have a milky white
appearance. Lack of the classic milky white appearance may occur in some instances of
malnutrition, which may occur is patients with advanced disease [13]. The characteristic
feature of a chylous effusion is an elevated triglyceride level which is present whether the
effusion is milky or not, and can differentiate it from other milky effusions such as a
cholesterol effusion. Chylous effusions are generally exudative, however about 15% are
transudative in nature [13]. A triglyceride concentration of more than 110 mg/dL, or the
presence of chylomicrons in the pleural fluid have been established as the criteria to confirm
the presence of a chylothorax [2,13]. In a study performed by Staats et al, all pleural
effusions reviewed with a triglyceride level greater than 110 mg/dl were found to be chylous,
while a triglyceride level less than 50 mg/dl excluded the diagnosis [14]. In cases suggestive
of a chylous effusion where the triglyceride level is between 50 and 110, a lipid
electrophoresis to detect the presence of chylomicrons can be performed.
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As with other types of pleural effusion, dyspnea and orthopnea are the most common
symptoms of chylothorax. Chest pain or infection are less frequent presenting symptoms as
chyle is bacteriostatic and is not irritating to the pleura. In addition to respiratory
complications, chylothorax is associated with malnutrition and immunosuppression [15].
Chyle contains fat soluble vitamins and a significant amount of dietary calories from fat
intake. There are also lymphocytes present in the fluid, and as chyle leaks into the pleural
space, these substances are lost, predisposing the patient to immunodeficiency and
malnourishment. In a patient with CLL, who is already immunosuppressed and often
hypogammaglobulinemic, this can become a significant concern and should be considered a
factor when deciding therapeutic options for the management of CLL.

Author Manuscript

Therapy to decrease the complications of chylous effusions aims to treat the underlying
condition. Additionally there are conservative surgical interventions, which can help
improve the patient symptoms. Conservative management entails draining the effusion,
either by thoracentesis or long term indwelling catheter, repleting lost nutrients along with
the institution of a low fat, medium-chain triglyceride diet. This diet contains fats that are
directly absorbed into the portal system, bypassing the intestinal lymph system [16].
Repeated pleural drainage can treat the symptoms related to the effusion, but continued
chyle drainage effectively depletes proteins and lymphocytes, thus negatively impacting the
immune system [15,17]. The surgical options include video-assisted thorascopic procedures
with pleurodesis to cause adhesion of the visceral and parietal pleura or a more invasive
pleurectomy which involves complete decortications of the visceral and parietal pleura [18].
Surgical therapy is less common as medical thorascopic talc pleurodesis has been shown to
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have very good success rates, with minimal complications in the prevention of recurrent
pleural effusions in patients with chemotherapy and/or radiation therapy refractory
lymphoma [15].
Pleuroperitoneal shunts have been proposed as an alternative to more invasive surgery and
have been effective in resolving chylothorax in small case series. Pleuroperitoneal shunting
has been used as an option for palliation of dyspnea by decreasing pleural fluid levels, while
allowing the chyle to flow into the peritoneal cavity where it may be absorbed, allowing for
some retention of nutritional and immunological value. Shunting also appears to cut hospital
costs, decrease iatrogenic complications and decrease symptoms, without subjecting the
patient to a thoracotomy [6,15]. However, shunts are falling out of favor due to difficulties
with shunt failure, often due to shunt occlusion or infection. None of the patients with CLL
had this therapeutic modality due to infection risk concerns.

Author Manuscript

Ligation of the thoracic duct is another intervention that has been reported to successfully
resolve a chylothorax related to CLL, although the patient outlined in the cited case report
received thoracic duct ligation in combination with pleurodesis [9]. Finally, radiotherapy has
also been reportedly used with successful resolution of refractory chylothorax, as described
in the case above. This has also been reported in a patient with advanced follicular nonHodgkin’s lymphoma and bulky lymphadenopathy of the thoracic trunk [19]. In this case,
there was improvement of chylothorax after 7.5 Gy of radiotherapy, and complete resolution
after 20.4 Gy of radiotherapy, with no recurrence at 17 months of follow up.

Author Manuscript

However, in patients with CLL who are found to have chylous effusion the answer may be to
treat the underlying CLL, although the optimal CLL directed management is unclear.
Chylous effusions appear to be an indicator of progressive or worsening CLL and treatment
of the underlying source, the CLL, is what will be of most benefit to the patient. The role of
recently approved targeted agents such as ibrutinib and idelalisib is yet unclear as these
patients were excluded from participation in clinical trials on the basis of their effusions. In
the only patient that received commercially available targeted agents, he had symptomatic
relief however therapy had to be discontinued due to treatment-emergent toxicities.

Conclusion

Author Manuscript

In this case series, we present three patients with CLL who presented with pleural effusions
which were noted to be chylous in etiology. Chylous effusions may be caused by
malignancy, however they are rarely found in patients with a CLL diagnosis. Common
therapies to ease symptoms include thoracentesis, diet modification, talc pleurodesis, and
indwelling pleural catheters. Pleuroperitoneal shunting, thoracic duct ligation and
radiotherapy are less common interventions. Given that chyle contains significant quantities
of lymphocytes as well as fat soluble vitamins, it is important to entertain the possibility of a
chylothorax in the workup of a pleural effusion in patients with CLL, as this diagnosis
should factor into the clinicians overall treatment decision making process and initiation of
treatment for CLL.
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Patient

Age at
Presentation
of
Chylothorax/
Sex

Cytogenetics

IgHV Status

Other prognostic markers

Treatments

Symptoms

Outcome

Patient 1

78/M

13q deletion

Unknown

CD38 (−); Zap70 (−)

Interferon; Cladribine;
Pentostatin,
Cyclophosphamide and
Rituximab; Bendamustine
and Rituximab

Shortness of breath

Improvement
× 2 years with
Bendamustine
and Rituxan
(2 cycles)

Patient 2

81/F

11q deletion

Unknown

CD38(+)

Bendamustine and Rituxan

Shortness of breath

Marginal
improvement
after
Bendamustine
and Rituxan
(3 cycles)

Patient 3

77 / F

Unknown

Mutated

Unknown

Obintuzumab × 1 cycle;
Idelalisib; 2400 cGy RT

Shortness of breath

Improved
after 2400
cGy to
thoracic duct
and
mediastinum

IGHV: immunoglobulin heavy chain variable region genes; RT: radiation therapy.
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Cream Colored, Turbid

Cream Colored

Patient 2

Patient 3

RBC: red blood cell; LDH: lactate dehydrogenase.

Yellow, Cloudy

Patient 1

n/a

210

120

Pleural Fluid Nuc Cell Count (cell/ul)

n/a

860

8875

Pleural Fluid RBC Count (cell/ul)
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Color

Author Manuscript

Patient

113

236

112

Pleural Fluid Gluocose

2.2/4.5

5.1/6.5

3.3/5.8

Fluid / Serum Protein

1.6/3.1

2.9/3.2

2.8 / 4.2

Fluid/Serum Albumin
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Fluid Characteristics

319/415

147/275

122 / 194

Fluid/Serum LDH

311

n/a

347

Pleural Fluid Triglycerides

Author Manuscript

Table 2:
Sammartino et al.
Page 8

J Hematol (Brossard). Author manuscript; available in PMC 2018 October 05.

